AnaptysBio Stock: The Royalty Waterfall Is About To Reverse (NASDAQ:ANAB)

seekingalpha.com · 2026-07-29

AnaptysBio (ANAB) stock shifts to a lean royalty company tied to GSK’s Jemperli. Jemperli royalties escalate with sales. Read here for a detailed analysis.

TickrTrends take: AnaptysBio operates in the Healthcare sector and currently has an awaiting full valuation designation from TickrTrends, meaning a comprehensive valuation assessment has not yet been completed. The reported reversal in the company's royalty waterfall structure represents a significant shift in its cash flow dynamics that would be particularly relevant to monitor as TickrTrends conducts its full valuation analysis. Investors focused on valuation metrics should track how this structural change impacts the company's revenue recognition and financial projections going forward.

Read the full story at seekingalpha.com →